{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:47:57Z","timestamp":1788871677093,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1016\/j.ahj.2005.07.020","type":"journal-article","created":{"date-parts":[[2005,11,11]],"date-time":"2005-11-11T07:14:42Z","timestamp":1131693282000},"page":"899.e1-899.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Targeted pharmacological reversal of electrical remodeling after cardioversion\u2014Rationale and design of the Flecainide Short-Long (Flec-SL) trial"],"prefix":"10.1016","volume":"150","author":[{"given":"Paulus","family":"Kirchhof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Fetsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hanrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Meinertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Steinbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Lehmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Breithardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2005.07.020_bib1","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","article-title":"Impact of atrial fibrillation on the risk of death: the Framingham Heart Study","volume":"98","author":"Benjamin","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2005.07.020_bib2","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jama.290.8.1049","article-title":"A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study","volume":"290","author":"Wang","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2005.07.020_bib3","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2005.07.020_bib4","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa022913","article-title":"Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation","volume":"349","author":"Hylek","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2005.07.020_bib5","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMoa041018","article-title":"Catheter ablation for atrial fibrillation in congestive heart failure","volume":"351","author":"Hsu","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2005.07.020_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.hrthm.2004.09.028","article-title":"Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: results from the RAte Control versus Electrical cardioversion for persistent atrial fibrillation (RACE) study","volume":"2","author":"Hagens","year":"2005","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.ahj.2005.07.020_bib7","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1056\/NEJMoa041705","article-title":"Amiodarone versus sotalol for atrial fibrillation","volume":"352","author":"Singh","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2005.07.020_bib8","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(00)03230-X","article-title":"Rhythm or rate control in atrial fibrillation\u2014Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial","volume":"356","author":"Hohnloser","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2005.07.020_bib9","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMoa021328","article-title":"A comparison of rate control and rhythm control in patients with atrial fibrillation","volume":"347","author":"AFFIRM I","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2005.07.020_bib10","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa021375","article-title":"A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation","volume":"347","author":"Van Gelder","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2005.07.020_bib11","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/S0735-1097(03)00332-2","article-title":"Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation","volume":"41","author":"Carlsson","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2005.07.020_bib12","doi-asserted-by":"crossref","first-page":"2D","DOI":"10.1016\/S0002-9149(02)03373-8","article-title":"Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy","volume":"91","author":"Maisel","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2005.07.020_bib13","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1161\/01.CIR.101.11.1282","article-title":"Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks","volume":"101","author":"Mittal","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2005.07.020_bib14","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehi160","article-title":"A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA)","volume":"26","author":"Kirchhof","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2005.07.020_bib15","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0140-6736(02)11315-8","article-title":"Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial","volume":"360","author":"Kirchhof","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2005.07.020_bib16","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/01.CIR.100.4.376","article-title":"Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction","volume":"100","author":"Pedersen","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2005.07.020_bib17","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1161\/01.CIR.0000072793.81076.D4","article-title":"Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials","volume":"107","author":"Vermes","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2005.07.020_bib18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0735-1097(03)00577-1","article-title":"Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study","volume":"42","author":"Pappone","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2005.07.020_bib19","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1540-8159.2004.00426.x","article-title":"Cardiac surgery for arrhythmias","volume":"27","author":"Cox","year":"2004","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.ahj.2005.07.020_bib20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/01.CIR.0000022665.18619.83","article-title":"Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study","volume":"106","author":"Madrid","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2005.07.020_bib21","first-page":"1033","article-title":"Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials","volume":"49","author":"Miller","year":"2000","journal-title":"J Fam Pract"},{"key":"10.1016\/j.ahj.2005.07.020_bib22","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0735-1097(01)01587-X","volume":"38","author":"Fuster","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2005.07.020_bib23","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ehj.2004.04.015","article-title":"Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial","volume":"25","author":"Fetsch","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2005.07.020_bib24","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial","volume":"324","author":"Echt","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2005.07.020_bib25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(96)02149-6","article-title":"Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction","volume":"348","author":"Waldo","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2005.07.020_bib26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0008-6363(00)00119-X","article-title":"The potential for QT prolongation and pro-arrhythmia by non\u2013anti-arrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology","volume":"47","author":"Haverkamp","year":"2000","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ahj.2005.07.020_bib27","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1161\/01.CIR.92.7.1954","article-title":"Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats","volume":"92","author":"Wijffels","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2005.07.020_bib28","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0008-6363(01)00453-9","article-title":"Atrial fibrillation-induced atrial contractile dysfunction: a tachycardiomyopathy of a different sort","volume":"53","author":"Schotten","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ahj.2005.07.020_bib29","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0008-6363(00)00100-0","article-title":"Changes in atrial electrical properties following cardioversion of chronic atrial fibrillation: relation with recurrence","volume":"47","author":"Manios","year":"2000","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ahj.2005.07.020_bib30","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s00395-005-0513-4","article-title":"Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation","volume":"100","author":"Kirchhof","year":"2005","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.ahj.2005.07.020_bib31","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/01.CIR.0000055316.35552.74","article-title":"Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone","volume":"107","author":"Shinagawa","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2005.07.020_bib32","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1161\/01.CIR.102.2.260","article-title":"Widening of the excitable gap during pharmacological cardioversion of atrial fibrillation in the goat: effects of cibenzoline, hydroquinidine, flecainide, and d-sotalol","volume":"102","author":"Wijffels","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2005.07.020_bib33","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1540-8167.2000.tb00052.x","article-title":"A patient with \u201catrial torsades de pointes\u201d","volume":"11","author":"Kirchhof","year":"2000","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.ahj.2005.07.020_bib34","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1046\/j.1540-8167.2003.03165.x","article-title":"Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias in patients with long QT syndrome","volume":"14","author":"Kirchhof","year":"2003","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.ahj.2005.07.020_bib35","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1177\/009286150003400227","article-title":"Sequential and multiple testing for dose-response analysis","volume":"34","author":"Lehmacher","year":"2000","journal-title":"Drug Inf J"},{"key":"10.1016\/j.ahj.2005.07.020_bib36","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1111\/j.0006-341X.1999.01286.x","article-title":"Adaptive sample size calculations in group sequential trial","volume":"55","author":"Lehmacher","year":"1999","journal-title":"Biometrics"},{"key":"10.1016\/j.ahj.2005.07.020_bib37","series-title":"US Department of Health and Human Services","article-title":"Management of new onset atrial fibrillation (evidence report\/Technology assessment): Agency for Healthcare Research and Quality","author":"McNamara","year":"2001"},{"key":"10.1016\/j.ahj.2005.07.020_bib38","doi-asserted-by":"crossref","first-page":"44A","DOI":"10.1016\/0002-9149(92)91077-H","article-title":"Flecainide acetate in the prevention of paroxysmal atrial fibrillation: a nine-month follow-up of more than 500 patients","volume":"70","author":"Clementy","year":"1992","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2005.07.020_bib39","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/01.CIR.80.6.1557","volume":"80","author":"Anderson","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2005.07.020_bib40","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1056\/NEJMoa041233","article-title":"Outpatient treatment of recent-onset atrial fibrillation with the \u201cpill-in-the-pocket\u201d approach","volume":"351","author":"Alboni","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2005.07.020_bib41","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.7326\/0003-4819-139-12-200312160-00012","article-title":"Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography","volume":"139","author":"McNamara","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2005.07.020_bib42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1124\/jpet.102.046755","article-title":"Amiodarone-induced post-repolarization refractoriness suppresses induction of ventricular fibrillation","volume":"305","author":"Kirchhof","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ahj.2005.07.020_bib43","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/01.CIR.97.25.2567","article-title":"Post-repolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs\u2014antiarrhythmic and proarrhythmic effects","volume":"97","author":"Kirchhof","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2005.07.020_bib44","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1161\/01.CIR.91.9.2378","article-title":"Relation between repolarization and refractoriness during programmed electrical stimulation in the human right ventricle. Implications for ventricular tachycardia induction","volume":"91","author":"Koller","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2005.07.020_bib45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jacc.2003.08.027","article-title":"Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care","volume":"43","author":"Israel","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2005.07.020_bib46","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.ehj.2004.06.014","article-title":"Suppression of paroxysmal atrial tachyarrhythmias\u2014results of the SOPAT trial","volume":"25","author":"Patten","year":"2004","journal-title":"Eur Heart J"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870305007489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870305007489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:54:55Z","timestamp":1762077295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870305007489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["S0002870305007489"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2005.07.020","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2005,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted pharmacological reversal of electrical remodeling after cardioversion\u2014Rationale and design of the Flecainide Short-Long (Flec-SL) trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2005.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]}}